Keywords
epidemiology, global, registry, traumatic brain injury
The epidemiology of traumatic brain injury (TBI) is unclear – it is estimated to affect 27–69 million individuals yearly with the bulk of the TBI burden in low-to-middle income countries (LMICs). Research has highlighted significant between-hospital variability in TBI outcomes following emergency surgery, but the overall incidence and epidemiology of TBI remains unclear. To address this need, we established the Global Epidemiology and Outcomes following Traumatic Brain Injury (GEO-TBI) registry, enabling recording of all TBI cases requiring admission irrespective of surgical treatment.
The GEO-TBI: Incidence study aims to describe TBI epidemiology and outcomes according to development indices, and to highlight best practices to facilitate further comparative research.
Multi-centre, international, registry-based, prospective cohort study.
Any unit managing TBI and participating in the GEO-TBI registry will be eligible to join the study. Each unit will select a 90-day study period. All TBI patients meeting the registry inclusion criteria (neurosurgical/ICU admission or neurosurgical operation) during the selected study period will be included in the GEO-TBI: Incidence.
All units will form a study team, that will gain local approval, identify eligible patients and input data. Data will be collected via the secure registry platform and validated after collection. Identifiers may be collected if required for local utility in accordance with the GEO-TBI protocol.
Data related to initial presentation, interventions and short-term outcomes will be collected in line with the GEO-TBI core dataset, developed following consensus from an iterative survey and feedback process. Patient demographics, injury details, timing and nature of interventions and post-injury care will be collected alongside associated complications. The primary outcome measures for the study will be the Glasgow Outcome at Discharge Scale (GODS) and 14-day mortality. Secondary outcome measures will be mortality and extended Glasgow Outcome Scale (GOSE) at the most recent follow-up timepoint.
Traumatic brain injury (TBI) is a significant global health problem, which affects 27–69 million people every year. After-effects of TBI commonly affect the injured individuals for years. Most patients who sustain a TBI are from developing countries. Research has shown that there are differences in patients’ recovery after TBI between countries and hospitals. The causes of these differences are unclear and tackling them could improve TBI treatment worldwide.
To address this need, we have recently established the Global Epidemiology and Outcomes Following Traumatic Brain Injury (GEO-TBI) registry. The international collaborative registry aims to collect data related to the causes, treatments and outcomes related to TBI patients. This data will hopefully enable future research to elucidate the causes of the recovery differences between hospitals, which could lead to improved patient outcomes.
The GEO-TBI: Incidence study collects data from all TBI patients that are admitted to participating hospitals or undergo a neurosurgical operation due to TBI during a 90-day period. This study looks at the patient’s recovery at discharge using the Glasgow Outcome at Discharge Scale (GODS), and at the 2-week mortality. In addition, the study also evaluates recovery at the most recent follow-up timepoint.
We hope that this information will enhance our understanding on the causes, treatments, and commonness of TBI. The study results will also help local hospitals compare their treatment results to an international standard.
epidemiology, global, registry, traumatic brain injury
Traumatic brain injury (TBI) is a growing global health concern due to increasing and ageing populations in LMICs and high-income countries (HICs) respectively1. Despite the importance of TBI epidemiology in informing health service planning, research priorities, and public health policy, this remains poorly understood. TBI is estimated to affect 27–69 million people every year, although data from LMICs is scarce1,2.
The Global Neurotrauma Outcomes Study (GNOS) has recently demonstrated country- and hospital-level differences in the case mix, management, and outcomes of surgically treated TBI3. Of note, outcome variability between countries was almost entirely accounted for by their human development index (HDI). Highlighting opportunities to influence outcomes by identification and replication of best practice, significant between-hospital outcome variation was described within countries3.
To elucidate the observed differences in TBI epidemiology, case-mix and outcomes, and to pave the way for comparative effectiveness research, systematic data collection of all TBI patients is needed4. To address this need, the Global Epidemiology and Outcomes following Traumatic Brain Injury (GEO-TBI) registry has been established. The registry is an international registry for recording TBI, with the core dataset focusing on injury mechanisms, initial presentation, interventions, and short-term outcomes. Any centre treating TBI is welcome to join the registry, and further information on protocols and documentation is available on the registry website.
The GEO-TBI: Incidence is the first collaborative study to run on the GEO-TBI registry. It is a multi-centre, international, prospective observational study, that aims to describe global TBI epidemiology based on real-world clinical data using the core dataset of the GEO-TBI registry via a snapshot design – all TBI patients admitted to the local hospital during a 90-day window will be included in the study. It is expected that data collection will be continued after the conclusion of the initial collection period as part of the GEO-TBI registry collaborative.
2) Examine differences in patient demographics, mechanisms of injury, and baseline clinical characteristics alongside indications, means and outcomes of TBI management.
3) Establish an international benchmark as a basis to compare outcomes in future clinical audits, epidemiological and intervention effectiveness research.
4) Compare the settings and resources of TBI management with regard to development indices.
5) Demonstrate the feasibility of collaborative registry data collection in an international setting and encourage ongoing prospective data collection.
6) Expand and empower the international network of neurotrauma professionals to conduct collaborative TBI research.
A team of lead investigators from the NIHR Global Health Research Group on Neurotrauma will be responsible for co-ordinating the GEO-TBI: Incidence study.
Each participating institution will form a local study team consisting of the senior study lead, data collectors, optional additional members and an independent data validator. The validator will work independently to the rest of the local team and will perform local data validation after its collection as outlined under Data capture and validation. Local teams may consist of a mix of surgeons, physicians, research associates and/or trainees. On centre registration, a Data Sharing Agreement outlining data processing will be formulated and the participant site profile questionnaire (Table 1) will be completed by the centres.
The GEO-TBI registry follows the International Committee of Medical Journal Editors criteria for authorship. In addition, all members of the local study teams will be listed individually as PubMed-citable GEO-TBI collaborators in any central reporting output. In any other manuscripts arising from the GEO-TBI dataset (such as participant centre-initiated projects), members of the local teams who participated in the corresponding project should be listed as authors or PubMed-citable collaborators. In any publications arising from GEO-TBI-based data, it is expected that the GEO-TBI collaboration is acknowledged.
• Co-Principal Investigators – Peter Hutchinson, Angelos Kolias and Alexis Joannides
• Study Research Fellow – Tommi Korhonen
• Protocol Development Group – Thomas Bashford, Ronnie Baticulon, David Clark, Indira Devi Bhagavatula, Ignatius Esene, Rocio Fernandez-Mendez, Anthony Figaji, Deepak Gupta, Tariq Khan, Tsegazeab Laeke, Michael Martin, David Menon, Midhun Mohan, Wellingson Paiva, Kee Park, Andres Rubiano, Vijaya Sekhar, Hamisi Shabani, Kachinga Sichizya, Davi Solla, Manjul Tripathi, Abenezer Tirsit, Sara Venturini
• Honorary Advisory Panel – Bart Depreitere, Corrado Iaccarino, Laura Lippa, Andrew Reisner, Gail Rosseau, Franco Servadei, Rikin Trivedi, Vicknes Waran
Data ownership remains with the participating centres in accordance with the GEO-TBI protocol. As per the GEO-TBI protocol, data is processed on behalf of the participating unit by Orion MedTech CIC (a not-for-profit organisation) independently of the central study team. Data will be collected and stored on a secure online platform Anonymised aggregate data will be shared with the central study team to enable analysis as outlined in the Data Sharing Agreement. Collection of identifiable data is supported by the platform, but not required in order to participate to GEO-TBI: Incidence or the GEO-TBI registry in general. If identifiable data is decided to be collected by the participating units, any identifying data will be kept strictly confidential and accessible only for local use. A detailed explanation is available in the GEO-TBI registry protocol.
Local collaborators will be given access to their own data after completion of the study to enable comparison of local practice with regional or international standards. Named collaborators will be able to request access to the entire data set or a subset of the data to perform post-hoc analyses to answer a defined research question. The study dataset will also be included in the aggregated core registry data reports and benchmarking.
Centre inclusion criteria
Any hospital or clinic worldwide offering acute TBI treatment (surgical and/or non-surgical) and participating in the GEO-TBI registry will be eligible to join the study.
Patient inclusion criteria
All adult and paediatric patients admitted to the participating institution with a traumatic brain injury during the selected 90-day inclusion period are eligible for inclusion in the GEO-TBI: Incidence study. The inclusion criteria are the GEO-TBI core registry criteria:
AND at least one of:
Neurosurgical admission with TBI
Intensive care unit (ICU) admission with TBI
Neurosurgical procedure(s) for TBI
Patient exclusion criteria
Patients receiving elective (planned admission) procedures or admission.
The GEO-TBI registry core dataset (Table 2) will be collected on all patients admitted to the participating unit due to TBI during in the study period. The collected data consists of 3 sub-sections – injury/admission data, operative data and outcome data. The dataset was formed via an international iterative consensus-based approach comprising an initial face-to-face meeting between a network of neurotrauma professionals from LMICs and HICs, an international survey to ensure usefulness and feasibility of the dataset in a variety of healthcare settings, and a final consensus meeting to define the final dataset. A publication outlining this process and the registry protocol is currently under peer review.
Demographic data | |
---|---|
Name | Surname, forename |
Date of birth | dd.mm.yyyy |
Sex | Male/female |
Unique patient ID number | CHI number/NHS number/National patient identifier |
Hospital | Choose from participating hospitals |
Injury data | |
Date and time of injury | dd.mm.yyyy, hh:mm |
Mechanism of injury | Select one: Fall: level/<2m/≥2m Vehicle collision: car/motorcycle/pedestrian/bicycle/other Assault: firearm/blade/blunt Blast Not otherwise specified: occupational/recretional/self-harm/other/unknown |
Primary intracranial injury Secondary intracranial injury | Select one: Scalp injury Fracture of skull vault Base of skull fracture Compound fracture of skull Concussion Diffuse brain injury Focal brain injury or contusion Extradural haematoma Acute subdural haematoma Chronic subdural haematoma Traumatic subarachnoid haemorrhage Traumatic intraventricular haemorrhage Injury to cranial nerve Unspecified injury to head No secondary intracranial injury |
Presence of major extracranial injury | Yes/No |
Initial GCS * | Eye, Verbal, Motor: 1–4, 1–5, 1–6, respectively |
Pupil reactivity * | Left, right: Yes/No/Unassessable |
Focal neurological deficit | Yes/No/Unassessable |
ASA grade | I–V |
Secondary transfer | Yes/No |
Systolic blood pressure prior to resuscitation | Millimetres of mercury, option for unknown |
SpO2 prior to resuscitation | %, option for unknown |
Imaging data | |
No imaging performed | Tick if no imaging |
If imaging performed: | |
Date of initial CT head | dd.mm.yyyy |
Imaging pathology present | Select if present: |
Extradural haematoma Subdural haematoma Contusion Fracture Intraventricular blood Traumatic subarachnoid haemorrhage | |
Midline shift on initial CT | Millimetres |
Obliteration of basal cisterns | Select one: Normal Compressed Absent |
Admission data | |
Date and time of hospital admission | dd.mm.yyyy, hh:mm |
Pre-hospital intubation | Yes/No |
Treatment | Non-operative management only If operatively managed, select if conducted: Washout or debridement (including penetrating injury) ICP monitoring EVD Burrhole(s) Fracture elevation Craniotomy Craniectomy Posterior fossa decompression Other surgical procedure |
Intracranial infection during admission | Yes/No |
Intubation † | Yes/No If Yes: Dates of intubation & extubation or tracheostomy (dd.mm.yyyy) Extubation Tick one: Independent ventilation/tracheostomy/terminal |
Intensive care unit admission | Yes/No If Yes: Dates of ICU admission & discharge dd.mm.yyyy |
In-hospital mortality | Yes/No If No: Glasgow Coma Scale at hospital discharge Eye, Verbal, Motor: 1–4, 1–5, 1–6, respectively |
Glasgow Outcome at Discharge Scale | 1-8 |
Date of hospital discharge | dd.mm.yyyy |
Outcome data | |
Date of assessment | dd.mm.yyyy |
Extended Glasgow Outcome Scale | 1–8 |
* Initial GCS and pupil status: after resuscitation, pre-intubation or at presentation if not intubated.
† Intubation other than solely for surgery. For example, if the patient was only intubated for intraoperative anaesthesia (e.g. surgery of subdural and epidural haematomas causing only mild neurological impairment). If the patient was kept intubated postoperatively, they should be recorded as intubated.
Each institution lead will be asked to fill out a questionnaire on resources available for neurotrauma care and rehabilitation in their healthcare setting. Finally, the data will be validated by the local independent validator as described under Data capture and validation.
Local study teams can select any 90-day period as their data input period. From the date of their injury, teams must follow patients up for a minimum of two weeks. For example, if a team selects the 1st of March 2023 as their start date then they must include all patients who meet the inclusion criteria between then and the 30th of April 2023. Functional outcomes at the date of last follow-up will also be included as a secondary measure.
Primary outcome
The primary outcome measures for the study will be 14-day mortality and the Glasgow Outcome Scale at Discharge (GODS)5. The GNOS study demonstrated 14-day mortality as a useful and feasible outcome measure for data collection in a comparable setting comprising both LMICs and HICs3, and the GODS system has been validated by McMillan and colleagues to be a robust predictor of post-discharge recovery with capability to compensate for loss to follow-up5.
Secondary outcomes
Glasgow Coma Scale (GCS) at hospital discharge.
Intracranial infections during the admission.
Length of stay in hospital and intensive care.
GOSE at latest follow-up.
Data capture
Collected data will be stored exclusively on a secure web-based registry system within the Orion platform described earlier The platform enables the secure data collection, validation and storage in a standard (SQL) format and is compliant with NHS security standards (including the Information Governance toolkit). The feasibility of data collection was confirmed in an internal pilot.
Data validation
Data validation will occur by two mechanisms:
• Web-based forms in the registry will contain fixed options at the point of data entry to maximise the likelihood of accurate and complete data capture from the outset.
• A local data validator independent of the local study team will be appointed at every participating site. After the 90-day study period chosen by the local team has ended, the data validator will be asked to retrospectively identify all patients admitted to their hospital during the 90-day period and complete the Data Validation Form (Table 3).
The overall mortality after surgically and non-surgically managed TBI is not well known. Studies with differing methodologies suggest highly varying estimates of the worldwide yearly TBI incidence. Extrapolating data from road traffic injuries, Dewan et al. suggest that between 64–74 million TBIs occur yearly with the highest incidence in Northern America and Europe, whereas the absolute TBI burden was found to be highest in resource-poorer regions2. A review based on the Global Burden of Disease Study 2016 suggested a TBI incidence of 27 million/year, but noted that this is probably an underestimate, as the results were derived predominantly from hospital-based sources1. Indeed, 70–90% of treated TBI (presenting to secondary care) is of mild severity, which probably represents 17–30% of all mild TBI6,7. A survey study showed that the incidence of TBI varied from <1% in China to almost 15% in Mexico suggesting a broad range of incidence rates across both LMICs and HICs8. There is a consensus that the incidence of TBI is likely increasing – in HICs due to population ageing9, and in LMICs due to increasing motorisation leading to more road traffic injury-related TBIs10. The Lancet Neurology Commission on TBI reported that an international consensus is needed on standardised epidemiological monitoring of TBI to allow the measurement of its incidence and mortality as well as comparison of access to care11. The GEO-TBI collaboration is a step towards this direction.
Mortality
Data on TBI outcomes in relation to development indices is scarce. Data from GNOS confirmed previous reports indicating that most surgically managed TBIs in HICs are severe, but mild-to-moderate TBI is more prevalent in the medium and low HDI tier countries3. Furthermore, the pathologies varied in relation to the HDI tiers, patient age and injury mechanisms. Surgeries in very high and high HDI tier countries were conducted more commonly due to acute subdural haematomas, whereas epidural haematomas and skull fractures were more common in medium and low HDI tier countries, respectively. Correspondingly, patients were oldest in higher HDI countries and youngest in low HDI countries – falls were the most common cause of injuries in HICs, whereas road traffic accidents and violence were the prominent mechanisms in medium and low HDI tiers, respectively3, which corresponds with research discussed under Epidemiology. Most between-country variation in TBI surgery outcomes was explained by HDI3.
In GNOS, fourteen-day mortality following emergency surgery for severe TBI was 33% in very high HDI tier countries, 31% in high HDI tier, 43% in medium HDI tier and 27% in low HDI tier countries3, which is in line with previous research suggesting a long-term mortality of 30% in HICs, but in contrast to earlier results indicating a mortality of 51% in LMICs for severe TBI12. The mechanism behind this difference is unclear – it is possibly related to country-level differences in patient selection for surgery and pre-hospital management of TBI. This highlights the rationale for the GEO-TBI: Incidence study to help elucidate the basis for this discrepancy.
Incidence of TBI in individual unit catchment areas during a consecutive 90-day period will be determined. To account for case mix and interventions, a logistic regression model will be constructed. In the model, patient-, institution- and country-level confounders are adjusted for. Patient-level confounders include age, GCS, pupillary reactivity, major extracranial injury; the hospital in which the patient is managed is the institution-level confounder; and country-level confounders include the country and its HDI tier.
Time from injury to imaging
The UK National Institute of Clinical Excellence (NICE) guidelines for investigation of suspected clinically significant acute head injuries suggests that such patients should be assessed on arrival in the emergency department, and a CT head should be conducted within one hour of arrival13. A large European dataset showed that a shorter time from TBI leading to GCS 9-12 to CT head scan was associated with reduced time to intervention and ED stay times, but not with mortality or worse outcomes14.
Time from injury to intervention
Mortality after trauma craniotomy increases sharply, if the procedure is conducted more than four hours after injury15,16. In GNOS, the median delay from injury to intervention was eight hours. The median delays from injury to admission, admission to operation and injury to operation were highest in low HDI tier countries, and lowest in high HDI tier countries with significant HDI tier-related variation. Importantly, even in the very high HDI tier, the time from injury to surgery exceeded four hours in half of such cases – in the low HDI tier, the lower quartile times in all of the above categories were four hours or longer3.
Infections
Post-craniotomy infection rates in recent large studies have been reported to be 5-7%17,18. In GNOS, the surgical site infection rate was 3%, though the 14-day follow-up period is probably not sufficient to characterise the total incidence of surgical site infections.
GOSE
The GOSE is not a sufficient measure of neurological outcome after the 14-day follow-up applied in the GEO-TBI: Incidence study. On the other hand, long-term follow-up may be altogether infeasible in certain settings. Therefore, the GOSE will be measured at the most recent available follow-up as a secondary outcome. GOSE scores typically increase within the first year after moderate-to-severe TBI patients19, but seem to plateau in longer-term follow-up20.
Statistical advice was provided by the MRC Biostatistics Unit, University of Cambridge. We plan to stratify the countries in which the participating units are situated in relation to their HDI index (very high, high, medium and low) as defined by the United Nations21 and successfully applied in the GNOS and the GlobalSurg studies3,22,23. The HDI is a tri-dimension composite measure comprising life expectancy index, education index and gross national income index, that consist of life expectancy at birth, expected and mean years of schooling, and GNI per capita, respectively.
Participating centres will be stratified based on their country into four groups based on their Human Development Index (HDI) rank, similar to the approach successfully used by the GlobalSurg studies16,17. The Human Development Index is calculated for each country based on life expectancy at birth, years of schooling, years of schooling and gross national income (GNI) per capita.
The GNOS highlighted disparities in case-mix and outcomes after emergency surgery for TBI, but it was not designed to assess the epidemiology of TBI, an area deficit of robust information. Data on TBI epidemiology may be used to inform different stakeholders, such as patients, care providers and policymakers, and to eventually guide data-driven decision-making and funding allocation. Indeed, the unavailability of data may impede funding opportunities as reports are commonly required by international funding providers and universities. Furthermore, the GEO-TBI: Incidence will form a basis for ongoing auditing and research intiatives as part of the GEO-TBI registry, and aims to provide insight to guide comparative effectiveness research. However, the methodology of the GEO-TBI: Incidence will not allow for evaluation of TBI that does not result in a hospital admission.
All data and results must be interpreted in the context of the participating units’ healthcare setting – for example, long-term follow-up may not be feasible in all settings. The epidemiological representativeness of the data depends on case ascertainment into the online registry. As such, the dataset was formed following an international consensus of neurotrauma care providers and it was kept sufficiently concise, while still capturing the most pertinent variables.
This study, as well as the GEO-TBI registry, will measure current practice and will not introduce any changes to current patient care. A part of the GEO-TBI registry, local approvals for the reporting of anonymised aggregate data will already be in place as part of the core registry enrolment process.
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: I have over 65 peer-reviewed publications in the field of neuroinjury in in vitro, in vivo and human studies. One of my current research fields is on traumatic brain injury, involving animal models, patient biosamples, and analysis of large clinical data sets.
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Traumatic brain injury
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 1 26 Jun 23 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Register with NIHR Open Research
Already registered? Sign in
If you are a previous or current NIHR award holder, sign up for information about developments, publishing and publications from NIHR Open Research.
We'll keep you updated on any major new updates to NIHR Open Research
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)